$LIFE News

Last published 1w ago

1w agoLIFEEthos Technologies Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoLIFEEthos Reports Third Quarter Fiscal Year 2026 Financial ResultsGlobeNewswireQ3 Revenue grew 151% year-over-year to $235 millionQ3 Direct Channel Revenue grew 112% year-over-year to $119 millionQ3 Third-Party Channel Revenue grew 209% year-over-year to $116 million AUSTIN, Texas, Nov. 02,
1w agoLIFEEthos Technologies Inc. Q3 2026 Earnings Call - ETHOS TECHNOLOGIES INCEarnings Call TranscriptsThank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Ethos Technologies, Inc. Q3 2026 earnings call. All lines have been placed on mu
2w agoLIFEEthos and Liberty Mutual Expand Relationship to Help Protect Who and What Matters MostGlobeNewswireAUSTIN, Texas, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company, and Liberty Mutual Insurance today announced an expansion of their strategic relationship that makes
1mo agoLIFEEthos to Announce Third Quarter 2026 Financial Results on November 2, 2026GlobeNewswireAUSTIN, Texas, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it will
2mo agoLIFEEthos to Present at the Goldman Sachs Communacopia + Technology ConferenceGlobeNewswireAUSTIN, Texas, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder and Chief
3mo agoLIFEEthos Signs Erin Andrews as Its Next Sports Partner in Growing Campaign to Make Life Insurance Accessible for Every FamilyGlobeNewswireAUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it has signed its next
3mo agoLIFEETHOS TECHNOLOGIES INC. Q2 2026 EARNINGS CALL - ETHOS TECHNOLOGIES INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Ethos Technology second quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will
3mo agoLIFEEthos Reports Second Quarter Fiscal Year 2026 Financial ResultsGlobeNewswireQ2 Revenue grew 113% year-over-year to $190 millionQ2 Direct Channel Revenue grew 131% year-over-year to $116 millionQ2 Third-Party Revenue grew 90% year-over-year to $73 millionBoard of Directors authorized a share
3mo agoLIFEEthos and North American Expand Their Indexed Universal Life Product Offering to include ChildrenGlobeNewswireAUSTIN, Texas and DES MOINES, Iowa, July 21, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the expansion of its
4mo agoLIFEEthos Partners with Amanda Kloots to Help Families Take Control of the One Thing They CanGlobeNewswireAUSTIN, Texas, July 14, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced a new campaign partnership with
4mo agoLIFEEthos to Announce Second Quarter 2026 Financial Results on August 3, 2026GlobeNewswireAUSTIN, Texas, July 02, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it will
5mo agoLIFEBAIRD 2026 GLOBAL CONSUMER, TECHNOLOGY & SERVICES CONFERENCE - ETHOS TECHNOLOGIES INCEarnings Call Transcriptswell thank you very much I'm Colin Sebastian the senior research analyst covering internet and internet services here at Bayard and we're really happy to have with us here in our afternoon session from ethos Peter Colas
5mo agoLIFE2026 Global Technology Conference - ETHOS TECHNOLOGIES INCEarnings Call TranscriptsAll right. Thank you, everyone, for joining us. We have Peter Collis with us here today, CEO of Ethos. Peter, thank you so much for your time and for making it out from South Bay. Thanks for being here, Mike. Appreciate
5mo agoLIFEEthos Partners with Baseball Legend David Ortiz to Champion Life Insurance as a Family Financial EssentialGlobeNewswireAUSTIN, Texas, May 21, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a new partnership with baseball icon and 3x world
6mo agoLIFEEthos to Present at Upcoming Investor ConferencesGlobeNewswireAUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder and Chief Executive
6mo agoLIFEEthos Announces Early Lock-Up ReleaseBusiness WireEthos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced the applicable price condition for a partial early lock-up release pursuant to the
6mo agoLIFEEthos Announces Early Lock-Up ReleaseGlobeNewswireAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced the applicable price condition for
6mo agoLIFEEthos Reports First Quarter Fiscal Year 2026 Financial ResultsGlobeNewswireQ1 Revenue grew 104% year-over-year to $193 millionQ1 Direct Channel Revenue grew 136% year-over-year to $146 millionQ1 Third-Party Revenue grew 42% year-over-year to $47 million AUSTIN, Texas, May 06, 2026 (GLOBE
6mo agoLIFEEthos Launches ChatGPT App To Bring Instant Life Insurance Estimates to 900 Million UsersGlobeNewswireAUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced the launch of
6mo agoLIFEEthos Collaborates with Liberty Mutual to Deliver a Modern, Digital-First Life Insurance ExperienceGlobeNewswireAUSTIN, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, and Liberty Mutual Insurance, today announced
7mo agoLIFEEthos to Announce First Quarter 2026 Financial Results on May 6, 2026GlobeNewswireAUSTIN, Texas, April 02, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it will
7mo agoLIFEEthos and Banner Life Expand Offering to Bring Final Expense Coverage to More FamiliesGlobeNewswireAUSTIN, Texas and FREDERICK, Md., March 24, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced an expansion of its
8mo agoLIFEEthos to Participate in The Citizens Technology ConferenceGlobeNewswireAUSTIN, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder and Chief Executive
8mo agoLIFEEthos Reports Fourth Quarter and Fiscal Year 2025 Financial ResultsGlobeNewswireRecords full-year revenue of $387.6 million, growing 52% year-over-yearAchieves Net Income of $24.6 million and Adjusted EBITDA of $25.8 million in Q4, reflecting a 22% margin and a 23% Adjusted EBITDA marginDelivers
11mo agoEXAS IDYA ILMN IR+6Quanterix Announces Board and Leadership Changes to Support Next Stage of GrowthBusiness WireAppoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company")
1y agoLIFEEthos Files Registration Statement for Proposed Initial Public OfferingGlobeNewswireAUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it filed a registration statement on Form
1y agoLIFEEthos and Lifeforce Team Up to Help Policyholders Live Longer, Healthier LivesGlobeNewswireAUSTIN, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a partnership with Lifeforce, the largest
1y agoEVR LIFE ATHInsurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of DirectorsGlobeNewswireAUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. Wheeler to its
2y agoLIFEaTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from "LIFE" to "ATYR"GlobeNewswireSAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from
2y agoLIFEaTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from
2y agoLIFEaTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International ConferenceGlobeNewswireSAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its
2y agoLIFEaTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisGlobeNewswireIndependent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024
2y agoLIFEaTyr Pharma to Present at Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
2y agoLIFEaTyr Pharma Announces First Quarter 2024 Results and Provides Corporate UpdateGlobeNewswirePhase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equivalents, restricted
2y agoLIFEaTyr Pharma to Participate in April Investor ConferencesGlobeNewswireSAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
2y agoLIFEaTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateGlobeNewswirePhase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing
2y agoLIFEaTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial ResultsGlobeNewswireSAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
2y agoLIFEaTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial ParticipantsGlobeNewswireIndividual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis. Company initiating program based on blinded EFZO-FIT™ study
2y agoLIFEaTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell DiversityGlobeNewswireFindings further demonstrate that efzofitimod modulates myeloid cells via the neuropilin-2 (NRP2) receptor to promote a unique anti-inflammatory mechanism. Role of NRP2 in immune system validated by activity of NRP2
2y agoLIFEaTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as AdvisorGlobeNewswireSAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its
2y agoLIFEaTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023GlobeNewswireSAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
3y agoLIFEaTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate UpdateGlobeNewswirePhase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated patient
3y agoLIFEaTyr Pharma to Present at November Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
3y agoLIFEaTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILDGlobeNewswireSAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its
3y agoLIFEaTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported OutcomesGlobeNewswirePost-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg efzofitimod group relapsed
3y agoLIFEaTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase
3y agoLIFEaTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate UpdateGlobeNewswirePhase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the third
3y agoLIFEEuropean Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Systemic SclerosisGlobeNewswireSAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase
3y agoLIFEaTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) ConferenceGlobeNewswirePresentations highlight efzofitimod's novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis. SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.